Growth Metrics

Oculis Holding AG (OCS) Total Debt (2021 - 2024)

Quarterly Total Debt changed N/A to $433067.9 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $433067.9 through Mar 2024, changed N/A year-over-year, with the annual reading at $426140.0 for FY2023, 99.66% down from the prior year.

Oculis Holding AG's Total Debt history spans 4 years, with the latest figure at $433067.9 for Q1 2024.

  • Total Debt came in at $433067.9 for Q1 2024, up from $426140.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $127.1 million in Q4 2022 to a low of $426140.0 in Q4 2023.
  • The 4-year median for Total Debt is $433067.9 (2024), against an average of $50.3 million.
  • Year-over-year, Total Debt rose 3.26% in 2022 and then crashed 99.66% in 2023.
  • Oculis Holding AG's Total Debt stood at $123.1 million in 2021, then rose by 3.26% to $127.1 million in 2022, then plummeted by 99.66% to $426140.0 in 2023, then grew by 1.63% to $433067.9 in 2024.
  • Per Business Quant, the three most recent readings for OCS's Total Debt are $433067.9 (Q1 2024), $426140.0 (Q4 2023), and $426821.5 (Q3 2023).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn 319.10 Mn
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - 110.96 Mn
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 1.99 Bn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn -
10 Oculis Holding AG 24.51 Bn 24.21 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2024 433,067.91
Dec 31, 2023 426,139.99
Sep 30, 2023 426,821.52
Dec 31, 2022 127.10 Mn
Dec 31, 2021 123.09 Mn